On Friday, in the course of current trade, Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), dropped -3.76%, and is now trading at $63.70.
AMAG Pharmaceuticals, declared the closing of its formerly declared underwritten public offering of common stock, counting the exercise in full by the underwriters of their option to purchase an additional 472,500 shares of common stock at the public offering price of $63.75 per share. The exercise of the underwriters’ option brought the total number of shares of common stock sold by AMAG to 3,622,500 and raised the total gross proceeds raised in the offering to about $230.9 million, before deducting the underwriting discounts, commissions and estimated expenses.
Jefferies LLC and Barclays Capital Inc. acted as joint book-running managers for the offering. Leerink Partners LLC acted as lead manager for the offering. Guggenheim Securities, LLC and Raymond James & Associates, Inc. acted as co-managers for the offering.
AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women with a singleton pregnancy; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the administration of oral mucocitis/stomatiits and various types of oral wounds.
During an Afternoon trade, Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), dipped -7.76%, and is now trading at $20.69.
Halozyme Therapeutics, declared the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a clinical research study of Halozyme’s investigational new drug, PEGPH20 in pancreatic cancer patients who are candidates for potentially curative surgery. The trial will be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center.
The Phase 2 study will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients with borderline resectable Pancreatic Ductal Adenocarcinoma (PDAC). The study will track the progress of up to 36 patients through chemotherapy and surgical treatment.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
Shares of Polycom Inc (NASDAQ:PLCM), during its Friday’s current trading session raised 1.01%, and is now trading at $11.02.
Polycom, declared that it has designated Gary Daichendt to the Polycom Board of Directors effective August 5, 2015. Daichendt’s expansive career as a senior officer of leading organizations provides him broad expertise in senior administration, strategy and operational excellence, in addition to an extensive understanding of the global IT industry.
Daichendt served as Executive Vice President Worldwide Operations at Cisco, where he was responsible for global sales, support, distribution, manufacturing and planned alliances. He spent eight years at Wang Laboratories, serving as its Vice President of Central Operations and Vice President of Marketing. He was also President and Chief Operating Officer at Nortel Networks and spent 10 years in various sales, marketing and administration positions at IBM.
Polycom, Inc. provides partnershipsolutions for voice, video, and content sharing. The company offers video, voice, and content-administration and content-sharing solutions, such as telepresence and conference room systems, home/work office solutions, applications for mobile devices, browser-based video collaboration, and cloud-delivered services, in addition to industry-specific solutions, counting specialized video carts and solutions for healthcare, education, and manufacturing.
Finally, HSBC Holdings plc (ADR) (NYSE:HSBC), lost -0.69% Friday.
HSBC Finance Corporation, declared that its board of directors declared the regular quarterly cash dividend on the company’s Series B preferred stock of $0.3975 per depositary share payable September 15, 2015, to stockholders of record as of September 1, 2015.
HSBC Holdings plc provides banking and financial products and services. It operates through four businesses Retail Banking and Wealth Administration, Commercial Banking, Global Banking and Markets, and Global Private Banking.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
